ReviewObstetrics and gynecology clinics of North America2022
Prevention of Cervical Cancer in Low-Resource African Settings.
Review in Obstetrics and gynecology clinics of North America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Financing of Human Papillomavirus Vaccination in Africa: A Scoping Review.Health science reports · 2026Review
- Navigating the divide - demographic and individual predictors of low HPV vaccine uptake in rural Uganda.BMC pediatrics · 2026Article
- Higher plasma AFB1 concentration is associated with increased risk of HPV 16 and HPV 18 detection and persistence among Ugandan women.Environmental health : a global access science source · 2025Article
- Implementation science research to understand the readiness of a mobile clinic intervention to screen for high-risk HPV infections and associated morbidity in Mali and Nigeria.Journal of global health economics and policy · 2025Article
- Meta-analysis of risk factors for recurrence in cervical cancer patients following fertility-sparing treatment.Frontiers in surgery · 2025Article
- Triptolide induces immunogenic cell death in cervical cancer cells via ER stress and redox modulation.American journal of cancer research · 2025Article
- Visual inspection with acetic acid and colposcopy: screening of cervical cancer in resource-limited healthcare settings.Frontiers in global women's health · 2025Article
- Long non-coding RNA LOXL1-AS1: a potential biomarker and therapeutic target in human malignant tumors.Clinical and experimental medicine · 2024Review
- Co-creation of human papillomavirus self-sampling delivery strategies for cervical cancer screening in rural Zimbabwe: nominal group technique.Frontiers in public health · 2023Article
- Characterization of Human Papillomavirus 16 from Kinshasa (Democratic Republic of the Congo)-Implications for Pathogenicity and Vaccine Effectiveness.Microorganisms · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Cervical cancer is a leading cause of cancer among women. Approximately 350,000 women die from cervical needlessly from cancer each year, and 85% of the global burden occurs in low- and middle-income countries (LMICs). Disparities in the incidence and mortality between LMICs and industrialized countries can be attributed to differences in access to human papillomavirus (HPV) vaccination and cervical cancer screening and treatment. The World Health Organization (WHO) is leading a renewed international effort to reduce the global burden of cervical cancer. In this article, we discuss recommendations for HPV vaccination, primary HPV screening, and treatment of precancerous lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.